--- The Results At the 6-month follow-up , the majority of patients reported measurable improvement in both pain scores and functional mobility
I don't want to be part of that model
Over the next five years, well almost certainly have better human trials, clearer safety data and a much better understanding of where BPC-157 genuinely has a place in medicine and where it doesnt. That may ultimately prove to be the real story
Unapproved peptides do not have established human dosing protocols, so users are essentially guessing at doses based on anecdotal reports
When treating a specific tendon, ligament, or muscle injury, injecting BPC-157 near the injury site concentrates the peptide where it is needed most
Accurate guidance makes planning easier